Cite
HARVARD Citation
Krebs, M. et al. (n.d.). 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). Journal for immunotherapy of cancer. p. A839. [Online].